- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05588271
A New Prediction Mode for Predicting the Risk of Pressure Injury in Patients Undergoing Liver Transplantation (PMPRPIULT)
Establishment of Risk Prediction Model for Pressure Injury in Patients Undergoing Liver Transplantation and Development of Prediction Tool
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: zheying Chen, Master
- Phone Number: 008613601853150
- Email: tougao2022@sina.com
Study Contact Backup
- Name: Xiaomei Chen, Master
- Phone Number: 008613918964297
- Email: xiaomeichen1989@163.com
Study Locations
-
-
-
Shanghai, China, 200127
- Recruiting
- Renji Hospital, School of Medicine, Shanghai Jiaotong University
-
Contact:
- Xiaomei Chen, Master
- Phone Number: 8613918964297
- Email: xiaomeichen1989@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- undergoing liver transplantation surgery (i.e., living-donor liver transplantation and deceased donor liver transplantation)
- patients undergoing the first surgery during their hospitalization
Exclusion Criteria:
- a history of PI before undergoing surgery
- patients with skin disease that could affect observation of skin and the outcome
- patients who died during surgery
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group with PIs
stage 1pressure injury: non-blanchable erythema of intact skin; stage 2 pressure injury: partial-thickness skin loss with exposed dermis; stage 3 pressure injury: full-thickness skin loss; stage 4 pressure injury: full-thickness skin and tissue loss; unstageable pressure injury: obscured full-thickness skin and tissue loss; deep tissue pressure injury: persistent non-blanchable deep red, maroon or purple discoloration
|
This study is an observational study.Exposure factors is patients with pressure injury.
|
Group without PIs
Skin in good condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
According to The National Pressure Ulcer Advisory Panel (NPUAP) defined the definition and stage of Pressure Injury to Judge whether pressure injury occurs on skin under pressure.
Time Frame: Within 6 hours after operation
|
Definition:A pressure injury is localized damage to the skin and underlying soft tissue usually over a bony prominence or related to a medical or other device. The injury can present as intact skin or an open ulcer and may be painful. The injury occurs as a result of intense and/or prolonged pressure or pressure in combination with shear. The tolerance of soft tissue for pressure and shear may also be affected by microclimate, nutrition, perfusion, co-morbidities and condition of the soft tissue. NPUAP Pressure Injury Stages:stage 1pressure injury: non-blanchable erythema of intact skin; stage 2 pressure injury: partial-thickness skin loss with exposed dermis; stage 3 pressure injury: full-thickness skin loss; stage 4 pressure injury: full-thickness skin and tissue loss; unstageable pressure injury: obscured full-thickness skin and tissue loss; deep tissue pressure injury: persistent non-blanchable deep red, maroon or purple discoloration |
Within 6 hours after operation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xiaomei Chen, Master, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2022-178-B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Rennes University HospitalCompletedLiver Transplantation | Kidney TransplantationFrance
-
Helsinki University Central HospitalTampere University HospitalCompletedLiver Transplantation | Kidney TransplantationFinland
Clinical Trials on Exposures
-
Centre des Sciences du Goût et de l'AlimentationEuropean Community; Regional Council of BurgundyCompletedConditioning of Caloric Adjustment and Liking in ChildrenFrance
-
Peking University Third HospitalEnrolling by invitationFemoroacetabular ImpingementChina
-
Johns Hopkins UniversityCompletedPancreatic Cancer | Neoplastic Cells, Circulating | Biological MarkersUnited States
-
Boston UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingCOVID-19 | Influenza | SARS-COV-2 Infection | Infant Morbidity | Perinatal Morbidity | Other Respiratory VirusesUnited States, India
-
Inova MedicalMerck Sharp & Dohme LLCRecruitingPost-Acute COVID-19 SyndromeBrazil
-
Hospices Civils de LyonCompletedInterstitial Lung Disease | Occupational ExposureFrance
-
AspetarCompletedImmobilization, Tonic | Hot Weather; Adverse EffectQatar
-
University Hospital, Strasbourg, FranceRecruitingSleep Disorders | Neurological Pathologies | Psychiatric Pathologies | Ophthalmological PathologiesFrance
-
Institut National de la Santé Et de la Recherche...RecruitingSarcoma | Occupational Exposure | Environmental Exposure | Life StyleFrance